Article Keyword Videos to Watch
Click on the image to start the video.
Images - Links - Articles
PPD Names James Streeter Executive Director of Electronic Data Capture
WILMINGTON, N.C. (April 3, 2006) – PPD, Inc. (Nasdaq: PPDI) today announced the appointment of James S. Streeter as executive director of electronic data capture (EDC). With EDC technology, study data entered directly at clinical sites can be accessed immediately by clinical project team members at other locations to expedite PPD review, processing and delivery to biopharmaceutical and medical device clients.
Streeter will work directly with clients to incorporate EDC into their development programs and will lead PPD's global EDC core team, providing project teams with the technical, process and training support services necessary to ensure proper deployment and execution during the critical startup, monitoring and close-out phases of clinical studies employing EDC. PPD has experience with a wide variety of EDC technologies, including two PPD-preferred technologies -- Oracle® Clinical Remote Data Capture (OC RDC 4.5) for clinical studies and PPD GlobalView for global registries and post-approval studies, both of which are fully supported by internal PPD resources and available globally.
Streeter brings to PPD more than 17 years of experience in EDC, data acquisition, data management and data analysis. Much of Streeter's EDC experience was gained at Pfizer Inc., where he most recently served as senior director of global clinical data services, heading the global data acquisition department for the company's global research and development organization. Prior to joining Pfizer, he was a senior hardware, software and systems engineer for the U.S. Navy with a focus in data acquisition and analysis.
"We expect Jim's vast experience and leadership will be especially beneficial to our project teams in executing clinical studies employing EDC," said Susan Atkinson, vice president of biostatistics and data management at PPD.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 27 countries and more than 8,300 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the anticipated value and contributions of the above-named employee and the prospects for our electronic data capture business, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments; loss of large contracts; competition within the outsourcing industry; continued success in sales growth; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
About the Author: News brought to you by PPD, an international contract research organization specializing in clinical trial management for the pharmaceutical, biotechnology, and medical industries.